Cipla exploring new customer deals for its China factory: Executive
Advertisement
Shanghai: Indian pharmaceutical giant Cipla is exploring entry into at least two new international markets for products manufactured at its factory in Jiangsu province, China, as part of a broader strategy to work around constrained production capacity in India.
The factory making inhalation respule products, began operations in 2024 and was initially set up to cater to the U.S. market.
"Sometimes we face capacity restrictions ... so they (customers) do approach us whether we can handle the supplies," Deepak Hegde, Cipla's general manager for China, told Reuters.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.